Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Active:	No
Cancer Type:	Cancer-Related Syndrome Leukemia Myelodysplastic Syndromes (MDS)	NCT ID:	NCT04313881
Trial Phases:	Phase III	Protocol IDs:	5F9009 (primary) NCI-2020-03406 2020-004287-26
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Gilead
NCI Full Details:	http://clinicaltrials.gov/show/NCT04313881

Summary

The primary objective of this study is to evaluate the efficacy of magrolimab in combination
with azacitidine compared to that of azacitidine plus placebo in previously untreated
participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised
International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and
overall survival (OS).

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.